Adaptive Biotechnologies Corp

ADPT10 Dec 2024
Healthcare
$6.39
+0.03 (+2.95%)
Lowest Today
$6.28
Highest Today
$6.69
Today’s Open
$6.39
Prev. Close
$6.27
52 Week High
$6.7
52 Week Low
$2.28
To Invest in Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Healthcare
ADPT10 Dec 2024
+0.03 (+2.95%)
1M
3M
6M
1Y
5Y
Low
$6.28
Day’s Range
High
$6.69
6.28
52 Week Low
$2.28
52-Week Range
52 Week High
$6.7
2.28
1 Day
-
1 Week
-3.83%
1 month return
+7.63%
3 month return
+46.83%
6 month return
+79.65%
1 Year return
+33.26%
3 Years return
-78.09%
5 Years return
-78.62%
10 Years return
-
Institutional Holdings
Viking Global Investors LP
20.32
Rubric Capital Management LP
9.76
BlackRock Inc
7.9
ARK Investment Management LLC
7.86
ARK Genomic Revolution
7.81
ARK Genomic Revolution ETF
7.27
Vanguard Group Inc
7.21

Market Status

Fundamentals
Market Cap
925.32 mln
PB Ratio
4.14
PE Ratio
0
Enterprise Value
773.82 mln
Total Assets
661.13 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Organisation
Adaptive Biotechnologies Corp
Employees
709
Industry
Biotechnology
CEO
Mr. Chad M. Robins M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities